Should I Buy Eli Lilly (LLY)? Finance YouTuber Analysis

The YouTuber recommends Eli Lilly for its long history of innovation in pharmaceutical treatments, which ensures future growth beyond current popular weight loss drugs. He emphasizes the company's decades of experience in R&D that consistently generate significant revenue and profits. He calculates a fair value of $1,474, making it attractive at its current price of $1,214.

“Additionally, you're getting Eli Lilly and an attractive price at $1,214. I calculated a fair value of $1,474.”

The analyst recommends buying Eli Lilly due to its strong innovation pipeline, evidenced by positive phase three results for Jaypirca and promising new weight loss treatments like retatrutide. The company demonstrates excellent profit margins and cash flow, and its valuation appears undervalued based on a discounted cash flow model, with a fair value of $1,443. Additionally, its low correlation to the macroeconomy offers valuable portfolio diversification.

“So, to answer the question, I still think Eli Lilly stock is an excellent stock to buy.”

The analyst recently bought Eli Lilly, calculating a fair value of $1,443, and sees it as undervalued. He highlights its market leadership in weight loss treatments and pipeline of innovative drugs. Additionally, he values its diversification benefit due to its low correlation with the macro economy.

“I'm excited to own shares of Eli Lilly. I'm also interested in adding more if the price remains anywhere near these levels.”

Eli Lilly is presented as a high-conviction buy, poised to be the first trillion-dollar healthcare company, driven by its highly successful weight loss drugs like Zepbound and Mounjaro. The company's substantial cash flow ($16 billion annually) and robust metabolic disease pipeline provide a strong competitive advantage, enabling continuous acquisition and development. Its operating profitability has significantly improved from 22% to nearly 39%, coupled with an impressive 41% revenue growth.

“Eli Lilly ticker LLY toying with a trillion dollar market cap now at $931 billion market cap going to be the first trillion healthcare company. its weight loss drugs producing a 400% return over the last 5 years.”

The analyst recommends Eli Lilly for its strong competitive advantages in metabolic disease and diabetes, particularly with its successful weight loss drugs like Zepbound and Mounjaro. The company boasts significant operating cash flow and a robust pipeline, including next-gen oral obesity drugs. Despite its high valuation, the projected surging revenue (41% this year, 20% next) and earnings growth (150% over two years) could justify continued upside, making it a solid long-term innovator.

“Lily's weight loss drugs could make it the first trillion dollar healthcare stock, but this also has strong competitive advantages in its metabolic disease and diabetes as well.”

The YouTuber believes Eli Lilly will continue to perform well, especially with the upcoming release of its pill-form weight loss drug. This positions it as a strong contender in the healthcare sector for an all-weather portfolio.

“Eli Liy, of course, the leader in those weight loss drugs and I think can continue to do very well, especially as it's pill form of that weight loss drug comes out.”

The analyst suggests Eli Lilly, noting its 22% decline over the last year. He considers it attractively priced and a good safety stock within the healthcare sector, which he identifies as a value sector during a potential market correction.

“Eli Liy very well attractively priced here ticker LY down 22% over the last year.”

While acknowledging Eli Lilly's strong pipeline and US manufacturing advantage, the analyst views it as a safer but less upside-potential alternative to Novo Nordisk in the GLP-1 market. It has also been affected by the compounded drug issue but not as severely as Novo Nordisk.

“It is safer than NVO. I think Eli Liy always has a stronger pipeline of new drugs and it also has US manufacturing which is going to be important...”

The YouTuber suggests Eli Lilly as a buy within the healthcare sector, which he identifies as trading at a discount to its long-term valuation and having a 20% upside to analyst price targets.

“In healthcare, that means names like United Health Group and Humanana, Eli Liy and Medronic.”

The YouTuber recommends Eli Lilly as a world-class drug maker, despite its higher valuation compared to Moderna. He points to its strong revenue growth, successful weight-loss drug Mounjaro, robust pipeline of late-stage drugs, and financial capacity to acquire growth.

“Instead, shares of Eli Liy, ticker LLY, are down 8% in the last year and an opportunity in a worldclass drug maker.”

The analyst suggests buying Eli Lilly if pharmaceutical tariffs are implemented, as the company already has significant US production. This would protect it from generic drug makers, which are primarily manufactured overseas, leading to a competitive advantage.

“Specifically here, Eli Liy ticker ly already has major US production and would benefit from protection against generics which are mainly manufactured overseas.”

The analyst recommends Eli Lilly as a safety investment within the healthcare sector, which is expected to post strong earnings growth. The pharmaceutical industry, in particular, is projected to have blowout earnings.

“within health care you might also look to the major drug makers like Eli Lily ticker Loi and fiser ticker PFE another safety investment would be the Vanguard Total Bond market fund”

The YouTuber highlights Eli Lilly as a top pharmaceutical pick within the healthcare sector, which is projected to experience substantial earnings growth in the coming year. He views it as a strong candidate for both safety and growth in the current market environment.

“within this group amen ticker amgn and Eli Lily ticker LL are the best positioned with in those Pharmaceuticals”

The YouTuber believes Eli Lilly's drug Manjaro has blockbuster potential, with significant weight loss results in trials and strong early prescription numbers. Despite current high valuations (68x earnings), he sees an opportunity to invest if the price pulls back, citing the company's strong drug pipeline and expected revenue growth.

“I still do think there's an opportunity to invest in Lily especially if that hype wears off a little and we get some price weakness.”

The YouTuber recommends Eli Lilly (LLY) as it has more room to run, having been up significantly recently. He implies it will exhibit a 'three green soldiers' pattern, indicating continued upward momentum.

“but that's Eli Lily it has more room to run so again one that should be on your radar and or watch list so you if you decide to play this can benefit.”

The YouTuber is buying Eli Lilly to gain exposure to the healthcare sector. This is part of a strategy to diversify and position for a potential rotation out of technology stocks.

“I'm playing healthc care with Eli Lily ticker symbol l l y”

The YouTuber expects Eli Lilly to continue its upward momentum, suggesting it will 'explode' further. He advises taking profits quickly once a gain is realized, implying a short-term trading opportunity.

“Eli Lily is going to explode as well okay it already exploded but look forward to do some more damage toor all right listen man I want you guys to make sure do me a favor in the morning when this is up at night $20 make sure you see profit take profit and then any pullbacks you can look to get back in and do your thing okay”

The YouTuber believes Eli Lilly will perform well this week, especially after its earnings report. He attributes this to strong sales driven by products like Ozempic, expecting the stock to go much higher despite potential guidance concerns.

“Eli Lily I got a feeling they're going to do their thing this week I I expect big things out of them with the OIC and everybody that's on that benefiting from that taking part in that their sales should be through the roof”

The YouTuber is adding Eli Lilly to his top 10 stocks for 2024 to gain exposure to the healthcare sector, which he feels is underrepresented in his current portfolio. He suggests using options to play the stock due to its high share price.

“Eli Lily has join the party I needed something in the health care sector.”

The YouTuber suggests buying Eli Lily stock, citing its recent increase in yearly forecast by $2 billion and the high demand for its GLP-1 drugs, which far outweighs its current production capacity. He also notes the company's heavy investment in AI for future growth.

“if you're on the fence on buying Eli Lily stock they just up their yearly forecast by $2 billion and they've Tapped Out on capacity while their demand on their products far outweighs what they can produce by several multiples”